Načítá se...
Continued EGFR Inhibition With Postprogression Chemotherapy: Where Do We Stand?
A growing body of evidence suggests that continuing EGFR inhibitors when switching to chemotherapy may not be the right choice for all patients. Nevertheless, a review of recent data about postprogression therapy for patients with EGFR-mutant lung cancer reveals some important caveats that must be c...
Uloženo v:
| Vydáno v: | Oncologist |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
AlphaMed Press
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4718438/ https://ncbi.nlm.nih.gov/pubmed/26500230 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2015-0370 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|